CD8A and neoplasm: Residual disease after PD-1/PD-L1 inhibitor therapy may be resistant to PD-1/PD-L1 inhibitor therapy, and LCT of residual disease may release tumor antigens from dead cells, which may resensitize residual disease to PD-1/PD-L1 inhibitor by activating natural killer cells or CD8+ T cells.